Bridge Creek Capital Management LLC Increases Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Bridge Creek Capital Management LLC increased its stock position in Thermo Fisher Scientific Inc. by 21.1% during the second quarter, bringing its total holdings to approximately $2 million.
• Other institutional investors have also significantly boosted their stakes, including Mondrian Investment Partners with a 146.1% increase and Foresight Group with a remarkable 3,242.7% boost in shares.
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43 per share, representing a 0.4% dividend yield for shareholders.

Bridge Creek Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,965 shares of the medical research company's stock after purchasing an additional 866 shares during the period. Bridge Creek Capital Management LLC's holdings in Thermo Fisher Scientific were worth $2,013,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. My Legacy Advisors LLC grew its stake in Thermo Fisher Scientific by 2.7% during the second quarter. My Legacy Advisors LLC now owns 2,554 shares of the medical research company's stock worth $1,100,000 after purchasing an additional 68 shares during the period. Thomasville National Bank grew its stake in Thermo Fisher Scientific by 73.0% in the second quarter. Thomasville National Bank now owns 34,529 shares of the medical research company's stock valued at $14,000,000 after acquiring an additional 14,573 shares during the period. Bell Bank grew its stake in Thermo Fisher Scientific by 4.4% in the second quarter. Bell Bank now owns 2,067 shares of the medical research company's stock valued at $838,000 after acquiring an additional 88 shares during the period. Perpetual Ltd grew its stake in Thermo Fisher Scientific by 43.9% in the second quarter. Perpetual Ltd now owns 399,937 shares of the medical research company's stock valued at $162,158,000 after acquiring an additional 121,999 shares during the period. Finally, IFM Investors Pty Ltd grew its stake in Thermo Fisher Scientific by 4.3% in the second quarter. IFM Investors Pty Ltd now owns 72,495 shares of the medical research company's stock valued at $29,394,000 after acquiring an additional 2,976 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TMO shares. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Finally, Robert W. Baird raised their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $588.35.

Thermo Fisher Scientific Stock Down 0.2%

TMO stock traded down $1.08 during trading on Friday, reaching $480.02. The stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company's 50 day moving average is $472.01 and its two-hundred day moving average is $449.50. The company has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a P/E/G ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.